Podcast

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

Author(s):

Urology Times staff

“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.

In this episode, Urology Times® Managing Editor Ben Saylor spoke with Amy E. Krambeck, MD. She discusses the recent Journal of Endourology study, "Multi-institutional prospective randomized control trial of novel intracorporeal lithotripters: ShockPulse-SE vs Trilogy trial," for which she served as senior author. Krambeck is a professor of urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Related Videos
Perry Xu, MD, answers a question during a Zoom video interview
Kate H. Kraft, MD, MHPE, FACS, FAAP, answers a question during a Zoom video interview
Hailey Frye answers a question during a Zoom video interview
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Thomas Chi, MD, MBA, answers a question during a Zoom video interview
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Related Content
FDA reports Urgent Device Field Correction notice for CVAC Aspiration System
March 21st 2025

FDA reports Urgent Device Field Correction notice for CVAC Aspiration System

Hannah Clarke
Calyxo has identified a new risk of injury when the CVAC System is used in patients with high viscosity fluid in their kidneys at the start of the procedure.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Kidney stone prevalence is increasing in women, study findings show
March 17th 2025

Kidney stone prevalence is increasing in women, study findings show

Hannah Clarke
The overall prevalence of kidney stones remained stable, with a notable increase observed among women.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
YOLT-203 shows promise in early phase 1 trial for primary hyperoxaluria 1
February 25th 2025

YOLT-203 shows promise in early phase 1 trial for primary hyperoxaluria 1

Hannah Clarke
YOLT-203 was granted an Orphan Drug Designation and a Rare Pediatric Disease Designation in September 2024.
FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1
February 5th 2025

FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1

Hannah Clarke
A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.
© 2025 MJH Life Sciences

All rights reserved.